| For: | Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568 [PMID: 36970588 DOI: 10.3748/wjg.v29.i10.1551] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v29/i10/1551.htm |
| Number | Citing Articles |
| 1 |
Lingbo Hu, Yongfu Xu, Yingli Qiao, Aidong Wang, Caidi He, Rongrong Wang. The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review. BMC Cancer 2025; 26(1) doi: 10.1186/s12885-025-15449-2
|
| 2 |
Sewoon Chun, Erin M Coyne, Jeffrey Meyer, Won Jin Ho. Durable Response to Combined Nivolumab, Lenvatinib, and Radiation Therapy Against Oligometastatic Hepatocellular Carcinoma. Cureus 2024; doi: 10.7759/cureus.73434
|
| 3 |
Sherif A. El-Kafrawy, Mostafa S. Elkafrawy, Esam I. Azhar, Anwaar Saeed, Ashraf A. Tabll. Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1533874
|
| 4 |
Cong-Cong Wang, Cai-Yan Yu, Jing Zhang, Rui Wang, Xiang-Shuo Kong. A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022). Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1159286
|
| 5 |
Dujinthan Jayabalan, Sugam Dhakal, Aarohanan Raguragavan, Akshat Saxena, Gary P. Jeffrey, Luis Calzadilla-Bertot, Leon A. Adams, Michael C. Wallace, Dirk Uhlmann. Hepatocellular Carcinoma and Health‐Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies. International Journal of Hepatology 2025; 2025(1) doi: 10.1155/ijh/1083642
|
| 6 |
Tania Payo‐Serafín, Carolina Méndez‐Blanco, Paula Fernández‐Palanca, Jennifer Martínez‐Geijo, María Reviejo, Juan José Ortiz‐de‐Urbina, Javier González‐Gallego, Jose J. G. Marin, José L. Mauriz, Beatriz San‐Miguel. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Clinical Pharmacology & Therapeutics 2024; 116(2) doi: 10.1002/cpt.3312
|
| 7 |
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni. Organoid as a promising tool for primary liver cancer research: a comprehensive review. Cell & Bioscience 2024; 14(1) doi: 10.1186/s13578-024-01287-5
|
| 8 |
Su Zhang, Zhou Fu, Fuyi Zhu, Xiaoying Gu, Huaqi Wang, Manqing Cao, Hua Guo, Ti Zhang. APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-β. Cell Death Discovery 2026; 12(1) doi: 10.1038/s41420-026-02984-5
|
| 9 |
Mohammad SS Naviwala, Daania Shoaib, Waqas A Khan, Adeeba Zaki. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian journal of hepato-gastroenterology 2024; 14(2) doi: 10.5005/jp-journals-10018-1455
|
| 10 |
Claudia R. Silver, Cynthia De la Garza-Ramos, John A. Stauffer, Umair Majeed, Jianfeng Wang, Beau B. Toskich. Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response. Radiology Case Reports 2024; 19(11) doi: 10.1016/j.radcr.2024.07.157
|
| 11 |
Khaled Mahmoud, Mahmoud Teaima, Yasmeen Attia, Jingjing Sun, Mohamed El-Nabarawi, Shady Swidan. Reprogramming hepatocellular carcinoma: Nanomedicine at the crossroads of molecular targets and smart delivery. Colloids and Surfaces B: Biointerfaces 2026; 268 doi: 10.1016/j.colsurfb.2026.115981
|
| 12 |
Gaoyong Hu, Haoyu Li, Renjing Su, Lifeng Han, Tao Wang, Haiyang Yu. Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies. Pharmacology & Therapeutics 2026; 280 doi: 10.1016/j.pharmthera.2026.108994
|
| 13 |
Madiha Younas, Muhammad Zubair, Muhammad Yousaf Shani, Samia Ahmad, Iqra Arshad, Wacław Jarecki, Muhammad Azmat, Ghulam Farid, Muhammad Yasin Ashraf, Lanlan Zhu. Molecular Docking of Phytochemicals Involved in Apoptotic Pathway and Their Interactions with CASP3, CASP9, and BAX in HepG2 Cell Line. Plants 2026; 15(12) doi: 10.3390/plants15121822
|
| 14 |
Manisri Porukala, P. K. Vinod, Amy McCart Reed. Gene expression signatures of stepwise progression of Hepatocellular Carcinoma. PLOS ONE 2023; 18(12) doi: 10.1371/journal.pone.0296454
|
| 15 |
Priyadarshini Mohapatra, Natarajan Chandrasekaran.
In vitro β-catenin attenuation by a mefloquine-loaded core–shell nano emulsion strategy to suppress liver cancer cells. Nanoscale Advances 2025; 7(3) doi: 10.1039/D4NA00547C
|
| 16 |
Ryo Yano, Masashi Hirooka, Yoshiko Nakamura, Yusuke Imai, Yohei Koizumi, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration. Clinical Journal of Gastroenterology 2024; 17(2) doi: 10.1007/s12328-023-01914-7
|
| 17 |
Qianming Kang, Luying He, Yang Zhang, Zhangfeng Zhong, Wen Tan. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions. Phytomedicine 2024; 130 doi: 10.1016/j.phymed.2024.155684
|
| 18 |
Zakria A Abdulal, Mohammed Y Altahhan, Abdulrahman F Qindil, Aseel M Al-Juhani, Manahel A Alatawi, Hanan M Hassan, Mohammed MH Al-Gayyar. Ferulic acid inhibits tumor proliferation and attenuates inflammation of hepatic tissues in experimentally induced HCC in rats. Journal of Investigative Medicine 2024; 72(8) doi: 10.1177/10815589241270489
|
| 19 |
Nadia Kim, Lisa Alcock, Silvia Del Din, Helen L. Reeves, Samuel T. Orange. Physical Activity and Hepatocellular Carcinoma Outcomes: a Narrative Review of Pre-clinical, Observational, and Interventional Evidence. Journal of Gastrointestinal Cancer 2026; 57(1) doi: 10.1007/s12029-026-01420-2
|
| 20 |
YU ZHANG, CHUNTING WANG, QIU LI, HAIYING PANG, FENGBO WU, GU HE, NAN ZHANG, PENG ZHANG. EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy. Oncology Research 2025; 33(2) doi: 10.32604/or.2024.043948
|
| 21 |
Mohd Suhail, Mohammad Tarique, Shams Tabrez, Darshan Badal. Leveraging AI and Natural Compounds: Innovative Approaches in the Diagnosis and Treatment of Hepatocellular Carcinoma. Current Pharmaceutical Design 2026; 32(30) doi: 10.2174/0113816128364693250117060342
|
| 22 |
Mohan Huang, Tian Lan, Xinyue Chen, Rong Chen, Xin Ding, William Chi-Shing Tai, Sze Chuen-Cesar Wong, Lawrence Wing-Chi Chan. Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2025; 26(10) doi: 10.3390/ijms26104766
|
| 23 |
Sumit Roy, Vancha Harish, Sharfuddin Mohd, Sachin Kumar Singh. Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment. Advanced Therapeutics 2024; 7(9) doi: 10.1002/adtp.202400126
|
| 24 |
David E. Kaplan, Ruoding Tan, Cheryl Xiang, Fan Mu, Sairy Hernandez, Sarika Ogale, Jiayang Li, Yilu Lin, Lizheng Shi, Amit G. Singal. Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers 2024; 16(20) doi: 10.3390/cancers16203508
|
| 25 |
Mohamed Asiri, Abdullah BinAbdu, Abdulrahman Al-Ammar, Abdulaziz Alsuaib, Abdullah Al-Shehri, Abdullah Almazyad, Ammar Aloufi, Najd AlGazlan, Haneen Alrajih, Mohammad Alkaiyat, Husam Ardah, Husam Shehata, Kanan Alshammari. Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia. Journal of Hepatocellular Carcinoma 2025; doi: 10.2147/JHC.S525984
|
| 26 |
Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu. Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab. Nutrition and Cancer 2025; 77(2) doi: 10.1080/01635581.2024.2415136
|
| 27 |
Yangyang Ou, Yiyu Chen, Kang Chen, Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan. Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort. The American Journal of Surgery 2025; 250 doi: 10.1016/j.amjsurg.2025.116602
|
| 28 |
Jinming Tian, Zeyu Zhang, Chao Cheng, Fei Yu, Tao Wang, Bin Cui, Ye Peng, Shuang Qiu, Fuming Wang, Weijing Cheng, Rong Luo, Guorong Jia, Changjing Zuo. In-situ ²²³Ra-doped calcium-alginate composite microspheres: a high-LET and immunoactivating platform for α-particle radioembolization in hepatocellular carcinoma. Journal of Nanobiotechnology 2026; 24(1) doi: 10.1186/s12951-025-03841-w
|
| 29 |
Chen Huang, Yangqian Li, Fengmei Zhang, Chenliang Zhang, Zhenyu Ding. Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. International Journal of Surgery 2025; 111(4) doi: 10.1097/JS9.0000000000002294
|
| 30 |
Megan E. Bannister, Devnandan A. Chatterjee, Shishir Shetty, Daniel A. Patten. The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential. International Journal of Molecular Sciences 2024; 25(23) doi: 10.3390/ijms252313167
|
| 31 |
Nojan Bajestani, Gavin Wu, Ahmed Hussein, Mina S. Makary. Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma. Biomedicines 2024; 12(7) doi: 10.3390/biomedicines12071432
|
| 32 |
Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Hiroyuki Suzuki, Hironori Koga, Ryoko Kuromatsu, Takumi Kawaguchi. Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma. Oncology 2024; doi: 10.1159/000541082
|
| 33 |
Shahad A Alshehri, Wasayf A Almarwani, Ajwan Z Albalawi, Shekha M Al-atwi, Khulud K Aljohani, Amjad A Alanazi, Mohamed A Ebrahim, Hanan M Hassan, Mohammed M Al-Gayyar. Role of Arctiin in Fibrosis and Apoptosis in Experimentally Induced Hepatocellular Carcinoma in Rats. Cureus 2024; doi: 10.7759/cureus.51997
|
| 34 |
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma. Advanced Science 2025; 12(13) doi: 10.1002/advs.202413682
|
| 35 |
Shui Liu, Qiao Li, Yongzhi Li, Jiyao Sheng. Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1325304
|
| 36 |
Ahmed S.G. Srag El-Din, Eman Hamza, Ahmed Y. Kira, Sameh Saber, Mona H. Zohny, Ohoud Y. Alshehri, Reham A. Al-Dhelaan, Eslam Osama Mohamed, Heba I. Elagamy. Engineering Selenium–Chitosan Nanoparticles for Enhanced Hepatic Delivery of Sunitinib and Improved In Vitro Anticancer Activity in Hepatocellular Carcinoma Models. Pharmaceuticals 2026; 19(6) doi: 10.3390/ph19060898
|
| 37 |
Zhao Ruan, Xuedan Sun. Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting. Hepatoma Research 2026; doi: 10.20517/2394-5079.2025.58
|
| 38 |
Adriana Castelo Caracas de Moura, Alessandro Rizzo, Thacio Albuquerque Bezerra Santos, Gustavo Benfatti Olivato, Fernando Sabino Marques Monteiro. Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis. BMC Cancer 2026; 26(1) doi: 10.1186/s12885-026-15893-8
|
| 39 |
Sahra Perseh, Reza Bafkary, Hossein Salmani, Mohammad Hassan Shahriari, Rassoul Dinarvand, Ismaeil Haririan, Seyedeh Sahar Mojtabazadeh, Sanaz Jamshidfar, Mohammad Akrami. Dual‐Targeted, pH/Reduction‐Responsive Mesoporous Silica Nanocarriers for Selective Sorafenib Delivery to Hepatocellular Carcinoma. Advanced Therapeutics 2026; 9(8) doi: 10.1002/adtp.202500581
|
| 40 |
Ahmed Mudher Al-Khaykanee, Soura Alaa Hussein, Z Muhsen M Ali. Role of 11β-hydroxysteroid dehydrogenase gene polymorphisms rs846910 and rs12086634 in the etiology of hepatocellular carcinoma. Biologica Nyssana 2025; 16(1) doi: 10.46793/BiolNyss.16.1.15A
|
| 41 |
Mohamed Kamal Shaker, Ashraf Omar, Hesham Elghazaly, Ghassan Aboualfa. Approach to Hepatocellular Carcinoma (HCC) Management in Low/Middle-Income Countries. 2025; doi: 10.1007/978-981-96-3894-9_8
|
| 42 |
Yitao Zheng, Jingna Hu, Yingna Mei, Yanjun Xiang, Haofeng Lu, Jiuting Zhu, Kaile Pan, Shuqun Cheng, Yang Liu. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-14516-y
|
| 43 |
Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou. Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation. Biochemical and Biophysical Research Communications 2025; 778 doi: 10.1016/j.bbrc.2025.152348
|
| 44 |
Junfeng Bu, Zihan Li, Die Hu, Ling Lan, Jiwei Huang, Xin Wang, Qiu Li, Jin Zhou, Yong Zeng. Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1554711
|
| 45 |
Yitao Zheng, Yanjun Xiang, Hongqi Shi, Zhuoqun Lin, Shuqun Cheng, Jiuting Zhu. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S461630
|
| 46 |
Yiran Li, Zonghan Liu, Yi Qian, Kang Wang, Yijun Gu, Yan Chen, Haozheng Jiang, Shuqun Cheng, Dong Jiang, Xinjun Lu. Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma. PLOS One 2025; 20(10) doi: 10.1371/journal.pone.0334099
|
| 47 |
Yang-Bo Zhu, Jia-Yi Qin, Ting-Ting Zhang, Wen-Jin Zhang, Qi Ling. Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature. World Journal of Gastrointestinal Surgery 2024; 16(10): 3312-3320 doi: 10.4240/wjgs.v16.i10.3312
|
| 48 |
Hongfu Cai, Jingwen Lin, Huide Zhu, Zhiwei Zheng. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. BMJ Open 2024; 14(12) doi: 10.1136/bmjopen-2023-079603
|
| 49 |
Peng Tang, Weixing Liu, Yating Xu, You Long, Yixiao Li, Jiaxin Li, Mingheng Liao, Xin Wang, Jin Zhou, Yong Zeng. Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1746990
|